RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 Myrcludex B Therapy Reduced HBV DNA and HDV RNA in Phase 2a Clinical Trial
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 48
SP 19
OP 20
DO 10.1177/155989771448014
UL http://mdc.sagepub.com/content/14/48/19.abstract
AB Chronic hepatitis B virus (HBV) infection is rarely cured with current therapies, and there is no effective therapy for hepatitis D virus (HBD) coinfection. Myrcludex B is a first-in-class entry inhibitor that inactivates the HBV and HDV receptor sodium taurocholate cotransporting polypeptide. This article discusses a phase 2a study evaluating the safety, tolerability, and antiviral efficacy of Myrcludex B.